'Drop-in' Intracavity Illuminator Wins Best in Cervical Care

SAN FRANCISCO, October 21, 2015 - Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, today announced that it has been recognized as a winner of Orthopedic This Week's 2015 Spine Technology Awards in the Cervical Care category. The annual awards, which were presented during the North American Spine Society's (NASS) Annual Meeting in Chicago in mid-October, recognize exemplary and innovative spine surgery products, and the engineering teams and inventors who create them.

The competition draws inventors and companies that have developed new products that improve patient outcomes from spine surgery, and applicants are judged according to their originality, clinical relevance, and likelihood that the technology will improve current standards of care. The judging panel of leading surgeons, educators and medical society leaders selected the Invuity Waveguide XT™ System as winner in the Cervical Care category, among 45 applicants.

The Waveguide XT System won based on its potential to solve a pressing clinical need: better intra-cavity visualization. As surgical philosophies shift towards less invasive techniques and smaller incisions, surgeons are operating in deep, dark cavities through smaller incisions with limited visibility. As such, the Waveguide XT System enables superior visualization of critical neural and vascular structures, enabling the surgeon to operate with more precision, efficiency and safety in and around the disc space, epidural space and lateral recesses. This allows spine surgeons to expand their use of less invasive surgical techniques that offer patients a faster recovery time, and that can help reduce the cost of care.

The Waveguide XT System is Invuity's first 'drop-in' intra-cavity illumination device. The drop-in modality allows it to be placed anywhere along the incision to provide stand-alone, hands-free, static illumination inside the surgical cavity. It broadly projects thermally cool, brilliant light to uniformly illuminate deep surgical cavities. The Waveguide XT System is compatible with any retractor, and can seamlessly integrate with any surgical approach, technique and instrumentation. Additionally, its low profile design accommodates preferred surgical exposure techniques.

'This recognition further demonstrates the role our illumination technology has in improving patient safety and surgeon efficiency in the operating room,' said Philip Sawyer, President and CEO of Invuity. 'By enhancing surgeons' visualization of critical structures during spine surgery in a safe and thermally cool way, we're working toward making Invuity's devices the standard of care in minimal access surgery.'

The Waveguide XT System uses Invuity's Intelligent Photonics™ technology to allow surgeons to safely and easily visualize tissue planes, critical structures and anatomical landmarks during spine procedures, such as anterior and posterior cervical decompression and fusion. The device can be placed within the incision to direct and shape the illumination deep into the surgical cavity, providing surgeons with clear visualization while eliminating the risk of thermal tissue damage, without altering a surgeon's technique or instrumentation.

For more information on the Invuity Waveguide XT System, please visit invuity.com/products/drop-ins/waveguide-xt/.

About Invuity®
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during minimally invasive and minimal access open surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.

Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding market opportunities and potential results from future new initiatives. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and 'Risk Factors,' which are on file with the Securities and Exchange Commission.

CONTACTS:
Media:
Stephanie Miceli
Waggener Edstrom
415-547-7018
media@invuity.com

Investors:
Matt Clawson
Pure Communications
949-370-8500
irdept@invuity.com

distributed by